[go: up one dir, main page]

AR006583A1 - Una composición farmacéutica - Google Patents

Una composición farmacéutica

Info

Publication number
AR006583A1
AR006583A1 ARP970101419A ARP970101419A AR006583A1 AR 006583 A1 AR006583 A1 AR 006583A1 AR P970101419 A ARP970101419 A AR P970101419A AR P970101419 A ARP970101419 A AR P970101419A AR 006583 A1 AR006583 A1 AR 006583A1
Authority
AR
Argentina
Prior art keywords
composition
pharmaceutical composition
salt
mycophenolate
immunosuppression
Prior art date
Application number
ARP970101419A
Other languages
English (en)
Inventor
Ching Pong Mak
Barbara Harberlin
Armin Meinzer
Jacky Vonderscher
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26309105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR006583(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9607564.3A external-priority patent/GB9607564D0/en
Priority claimed from GBGB9622028.0A external-priority patent/GB9622028D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR006583A1 publication Critical patent/AR006583A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Composición farmacéutica que comprende una sal de mcofenolato, estando la composición adaptada para liberar micofenolato en la parte superior del tractointestinal. Particulamente dicha composición comprende una sal de micofenolato farmacéuticamente aceptable con revestimiento entérico. También proporciona eluso de dicha composición farmacéutica en la preparación de un medicamento para inmunosupresión, particularmente para la prevención de rechazo de trasplante dehaloinjerto o xenoinjerto,na tivo o transgénico de órgano, tejido o de células; para el tratamiento o prevención de enfermedades mediadas por el sistema inmuney/o enfermedades inflamatorias. Asimismo proporciona un método para inmunosuprimir a un sujeto, el cualcomp rende administrar una cantidadterapéuticamente efectiva de dicha sal de micofenolato farmacéuticamente aceptable, con revestimiento entérico o dicha composición a un sujeto ennecesidad de inmunosupresión, opcionalmente con laadministración si multánea o separada de otro inmunosupresor.
ARP970101419A 1996-04-12 1997-04-10 Una composición farmacéutica AR006583A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9607564.3A GB9607564D0 (en) 1996-04-12 1996-04-12 Organic compounds
GBGB9622028.0A GB9622028D0 (en) 1996-10-24 1996-10-24 Organic compounds

Publications (1)

Publication Number Publication Date
AR006583A1 true AR006583A1 (es) 1999-09-08

Family

ID=26309105

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP970101419A AR006583A1 (es) 1996-04-12 1997-04-10 Una composición farmacéutica
ARP070100839A AR059693A2 (es) 1996-04-12 2007-03-01 Una composicion farmaceutica de micofenolato y su uso

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP070100839A AR059693A2 (es) 1996-04-12 2007-03-01 Una composicion farmaceutica de micofenolato y su uso

Country Status (34)

Country Link
US (3) US6025391A (es)
EP (2) EP0892640B1 (es)
JP (2) JP3779732B2 (es)
CN (1) CN1104238C (es)
AR (2) AR006583A1 (es)
AT (2) AT408415B (es)
AU (1) AU725388B2 (es)
BE (1) BE1010963A3 (es)
BR (1) BR9708624A (es)
CO (1) CO4900024A1 (es)
CY (1) CY2243B1 (es)
CZ (1) CZ291811B6 (es)
DE (4) DE19781690D2 (es)
DK (1) DK0892640T3 (es)
ES (2) ES2178510B1 (es)
FR (1) FR2747920B1 (es)
GB (1) GB2326339B (es)
GR (1) GR1002893B (es)
HK (1) HK1051484A1 (es)
HU (1) HU224919B1 (es)
ID (1) ID18663A (es)
IE (1) IE970267A1 (es)
IL (1) IL126431A (es)
IT (1) IT1297045B1 (es)
LU (1) LU91094I2 (es)
MY (1) MY119049A (es)
NL (1) NL300157I2 (es)
NO (2) NO322891B1 (es)
NZ (1) NZ332117A (es)
PT (1) PT892640E (es)
RU (2) RU2203659C2 (es)
TR (1) TR199802056T2 (es)
TW (1) TW457098B (es)
WO (1) WO1997038689A2 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4565000A (en) * 1999-05-10 2000-11-21 Novartis Ag Organic compounds
US20030050692A1 (en) * 2000-12-22 2003-03-13 Avantec Vascular Corporation Delivery of therapeutic capable agents
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
KR100978836B1 (ko) * 2001-10-19 2010-08-30 이소테크니카 인코포레이티드 신규한 시클로스포린 유사체 미세유화액 예비농축물
RU2277090C9 (ru) * 2002-08-29 2006-09-10 Байокон Лимитид Способ получения натриевой соли микофеноловой кислоты, являющейся иммунодепрессантным средством
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
GB0314553D0 (en) * 2003-06-21 2003-07-30 Weatherford Lamb Electric submersible pumps
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
JP5032300B2 (ja) * 2004-03-22 2012-09-26 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング 界面活性剤を含有している、リパーゼを含有する生成物の、とりわけパンクレアチンの経口医薬組成物
MXPA06005659A (es) * 2004-04-26 2007-04-10 Teva Gyogyszergyar Zartkoruen Proceso para preparacion de acido micofenolico y derivados de ester del mismo.
JP2007534697A (ja) 2004-04-27 2007-11-29 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ ミコフェノール酸モフェチルおよび他のミコフェノール酸エステルの調製方法
CA2573781A1 (en) 2004-07-20 2006-02-02 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Processes for preparation of crystalline mycophenolate sodium
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
WO2006086498A2 (en) 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors
US20060235070A1 (en) * 2005-02-08 2006-10-19 Hayden Michael R Compositions and methods for treating vascular, autoimmune, and inflammatory diseases
EP2278002B1 (en) * 2005-07-29 2017-07-12 Abbott Laboratories GmbH Pancreatin with reduced viral content
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
CN1985994B (zh) * 2005-12-19 2011-01-12 康泰乐(北京)医药科技发展有限公司 改进的包含霉酚酸盐的包有肠溶衣的药物组合物
RU2008136574A (ru) * 2006-02-13 2010-03-27 Новартис АГ (CH) Высокая дозировка микофеноловой кислоты (мфк)
JP2007230948A (ja) * 2006-03-02 2007-09-13 Univ Meijo 腸溶性化硬カプセル
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
ATE457358T1 (de) * 2006-06-29 2010-02-15 Ivax Pharmaceuticals Sro Regulation der säuremetabolitproduktion
US20080182998A1 (en) * 2007-01-25 2008-07-31 Apotex Fermentation Inc. Novel crystalline mycophenolate sodium polymorph and processes to manufacture same
US20080176937A1 (en) * 2007-01-23 2008-07-24 Apotex Fermentation Inc. Novel crystalline mycophenolate sodium polymorph and processes to manufacture same
TW200904982A (en) * 2007-04-11 2009-02-01 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Method for reducing impurity level in mycophenolic acid fermentation
RU2010109408A (ru) * 2007-08-13 2011-09-20 Панацея Биотек Лимитед (In) Композиции с пролонгированным высвобождением, включающие микофенолят натрия, и их действия
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
EP2310008A4 (en) * 2008-07-09 2014-03-05 Aspreva Internat Ltd MYCOPHENOLIC SODIUM ACID SOLUTIONS WITH PH SPECIFIC FOR THE TREATMENT OF OCULAR DISORDERS
WO2011046546A1 (en) * 2009-10-13 2011-04-21 Teva Pharmaceutical Industries Ltd. Delayed release compositions
US20110086102A1 (en) * 2009-10-13 2011-04-14 Teva Pharmaceutical Industries Ltd. Delayed release compositions
WO2011051967A2 (en) * 2009-10-23 2011-05-05 Alkem Laboratories Ltd Pharmaceutical compositions comprising mycophenolate and processes for preparing thereof
CN103880799A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
CN103880800A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
GB201100786D0 (en) 2011-01-18 2011-03-02 Ems Sa Pharmaceutical compositions of immunosuppressants
WO2013041205A1 (de) 2011-09-19 2013-03-28 Pyxirion Pharma Gmbh Neue therapeutische konzepte zur behandlung von gefässerkrankungen
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
NZ741985A (en) 2013-03-14 2019-12-20 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various diseases
WO2014167442A1 (en) 2013-03-26 2014-10-16 Wockhardt Limited Pharmaceutical compositions comprising mycophenolic acid or salts thereof
ES2785391T3 (es) 2014-01-06 2020-10-06 Shield Tx Uk Ltd Régimen de dosificación de trimaltol férrico
US9604922B2 (en) 2014-02-24 2017-03-28 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
GB201418710D0 (en) 2014-10-21 2014-12-03 Iron Therapeutics Holdings Ag Dosage regimen
US10213411B2 (en) 2015-08-27 2019-02-26 Vijaykumar Rajasekhar Use of prodrugs of fumarates in treating heart failure diseases
US10463642B2 (en) 2016-02-01 2019-11-05 Vijaykumar Rajasekhar Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate
WO2018170022A2 (en) * 2017-03-13 2018-09-20 Okava Pharmaceuticals, Inc. Methods and compositions for delivering mycophenolic acid active agents to non-human mammals
JP2024508327A (ja) 2021-03-03 2024-02-26 サナ バイオテクノロジー，インコーポレイテッド 心筋細胞療法と併用する免疫抑制療法、及び関連する方法ならびに組成物
CN114028334B (zh) * 2021-12-10 2023-08-29 卓和药业集团股份有限公司 一种肺部给药的免疫抑制剂的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1157099A (en) * 1966-09-27 1969-07-02 Ici Ltd Fermentation Process
GB1157100A (en) * 1966-09-27 1969-07-02 Ici Ltd Pharmaceutical Compositions
GB1173942A (en) * 1967-06-06 1969-12-10 Bellon Labor Sa Roger New 2,3-Dihydro-1,4-Benzoxazines
GB1158387A (en) * 1967-06-13 1969-07-16 Ici Ltd Procedure for Isolation of Mycophenolic Acid
GB1203328A (en) * 1968-06-04 1970-08-26 Ici Ltd Pharmaceutical compositions
GB1261060A (en) * 1969-09-09 1972-01-19 Ici Ltd Phthalen-1-one derivatives
US3705946A (en) * 1971-05-25 1972-12-12 Lilly Co Eli Method of treating hyperuricemia
US3825571A (en) * 1971-07-31 1974-07-23 Chugai Pharmaceutical Co Ltd Mycophenolic acid derivatives
JPS5542995B2 (es) * 1972-02-24 1980-11-04
US3868454A (en) * 1972-08-14 1975-02-25 Lilly Co Eli Psoriasis treatment with mycophenolic acid derivatives
US3777020A (en) * 1972-08-14 1973-12-04 Lilly Co Eli Psoriasis treatment with mycophenolic acid
US4005108A (en) * 1973-04-03 1977-01-25 Research Corporation Novel anti-leukemic diterpenoid triepoxides
US3880995A (en) * 1973-05-14 1975-04-29 Lilly Co Eli Treatment of arthritis with mycophenolic acid and derivatives
US3903071A (en) * 1973-05-22 1975-09-02 Lilly Co Eli Mycophenolic acid derivatives
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
US4234684A (en) * 1979-12-11 1980-11-18 Eli Lilly And Company Method of preparing mycophenolic acid glucoside
IT1150194B (it) * 1982-02-23 1986-12-10 Chiesi Farma Spa Formulazioni farmaceutiche ad attivita'antiinfiammatoria, analgesica,antipiretica e gastroprotettiva
US4680299A (en) * 1984-04-30 1987-07-14 E.I. Du Pont De Nemours And Company 2-phenyl-4-quinolinecarboxylic acids and pharmaceutical compositions thereof
US4686234A (en) * 1985-11-27 1987-08-11 Syntex (U.S.A) Inc. Mycophenolic acid derivatives in the treatment of inflammatory diseases, in particular rheumatoid arthritis
US4959387A (en) * 1986-01-23 1990-09-25 Syntex (U.S.A.) Inc. Mycophenolic acid derivatives in the treatment of rheumatoid arthritis
US4725622A (en) * 1986-01-23 1988-02-16 Syntex (U.S.A.) Inc. Mycophenolic acid derivatives in the treatment of rheumatoid arthritis
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
US4727069A (en) * 1987-01-30 1988-02-23 Syntex (U.S.A.) Inc. Heterocyclic aminoalkyl esters of mycophenolic acid, derivatives thereof and pharmaceutical compositions
US4847381A (en) * 1987-08-31 1989-07-11 American Cyanamid Company 2-Phenyl-4-quinoline carboxylic acids
US5135934A (en) * 1990-07-06 1992-08-04 Du Pont Merck Pharmaceutical Company 3-phenyl-5,6-dihydrobenz(c) acridine-7-carboxylic acids and related compounds as immunosuppressive agents
US5372298A (en) * 1992-01-07 1994-12-13 The Regents Of The University Of California Transient liquid phase ceramic bonding
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
CA2086642C (en) * 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
WO1994026265A1 (en) * 1993-05-06 1994-11-24 Pharmagenesis, Inc. 16-hydroxytriptolide composition and method for immunotherapy
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
US5428040A (en) * 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
RO115412B1 (ro) * 1993-10-01 2000-02-28 Syntex Inc Compozitie farmaceutica si procedeu de obtinere a compozitiei farmaceutice
AU5594794A (en) * 1993-11-08 1995-05-29 Pharmagenesis, Inc. Immunotherapy composition and method
WO1995014023A1 (en) * 1993-11-19 1995-05-26 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators

Also Published As

Publication number Publication date
GB2326339A (en) 1998-12-23
WO1997038689A2 (en) 1997-10-23
US6306900B1 (en) 2001-10-23
MY119049A (en) 2005-03-31
TW457098B (en) 2001-10-01
HK1051484A1 (en) 2003-08-08
RU2203659C2 (ru) 2003-05-10
IL126431A (en) 2005-03-20
BE1010963A3 (fr) 1999-03-02
HU224919B1 (en) 2006-04-28
ITRM970207A1 (it) 1998-10-11
IT1297045B1 (it) 1999-08-03
ATE259228T1 (de) 2004-02-15
US6172107B1 (en) 2001-01-09
AU725388B2 (en) 2000-10-12
JP2000503665A (ja) 2000-03-28
AU2384397A (en) 1997-11-07
NO984728D0 (no) 1998-10-09
CY2243B1 (en) 2003-07-04
LU91094I2 (fr) 2004-10-11
WO1997038689A3 (en) 1997-12-04
EP0892640B1 (en) 2004-02-11
CZ326798A3 (cs) 1999-01-13
EP0892640A2 (en) 1999-01-27
EP1221316A1 (en) 2002-07-10
DE19781690D2 (de) 1999-04-08
NZ332117A (en) 2000-04-28
NL300157I1 (nl) 2004-10-01
ID18663A (id) 1998-04-30
IE970267A1 (en) 1997-10-22
PT892640E (pt) 2004-06-30
ES2216141T3 (es) 2004-10-16
HK1016490A1 (en) 1999-11-05
CO4900024A1 (es) 2000-03-27
ES2178510B1 (es) 2004-08-16
DE122004000038I2 (de) 2006-04-27
FR2747920B1 (fr) 1999-12-31
GB9821304D0 (en) 1998-11-25
IL126431A0 (en) 1999-08-17
RU2615397C2 (ru) 2017-04-04
NL300157I2 (nl) 2004-12-01
JP2006063086A (ja) 2006-03-09
NO2007004I2 (no) 2009-10-19
ATA905997A (de) 2001-04-15
HUP9903373A2 (hu) 2001-04-28
JP3779732B2 (ja) 2006-05-31
US6025391A (en) 2000-02-15
TR199802056T2 (xx) 1999-02-22
NO322891B1 (no) 2006-12-18
CN1104238C (zh) 2003-04-02
GB2326339B (en) 2000-04-19
NO2007004I1 (no) 2007-04-16
DE69727559T2 (de) 2004-12-16
GR1002893B (el) 1998-04-10
HUP9903373A3 (en) 2001-05-28
NO984728L (no) 1998-12-02
FR2747920A1 (fr) 1997-10-31
DE69727559D1 (de) 2004-03-18
ES2178510A1 (es) 2002-12-16
AR059693A2 (es) 2008-04-23
BR9708624A (pt) 1999-08-03
DK0892640T3 (da) 2004-05-10
DE122004000038I1 (de) 2006-01-26
CZ291811B6 (cs) 2003-06-18
AT408415B (de) 2001-11-26
CN1215991A (zh) 1999-05-05

Similar Documents

Publication Publication Date Title
AR006583A1 (es) Una composición farmacéutica
RU98120360A (ru) Фармацевтические композиции на основе микофенолята с энтеросолюбильным покрытием
SI1131065T1 (en) Dialkylfumarates for the treatment of autoimmune diseases
RU98117915A (ru) Использование фармацевтической композиции, содержащей пептид, подавляющий аппетит
Karussis et al. Chronic-relapsing experimental autoimmune encephalomyelitis (CR-EAE): treatment and induction of tolerance, with high dose cyclophosphamide followed by syngeneic bone marrow transplantation
NO975334D0 (no) Anvendelse av flavanolignaner for fremstilling av medikamenter med antiproliferativ aktivitet i uterus, ovarium og bryst
JP2002527401A5 (es)
IL157841A0 (en) Activation of natural killer cells by adenosine a3 receptor agonists
NO931536L (no) Fremgangsmaater og sammensetninger for undertrykkelse av allograftforkastelse hos pattedyr
US20250152665A1 (en) Mutant Peptides And Methods Of Treating Subjects Using The Same
Siemionow et al. Advances in composite tissue allograft transplantation as related to the hand and upper extremity
LU88684I2 (fr) Complexe lipidique d'amphotericine b ainsi que leurs dérivés pharmaceutiquement acceptables (abelcet )
CO5060499A1 (es) Metodos y composiciones para el tratamiento de enfermedad de reflujo gastroesofagico
WO2001045715A3 (en) Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain
JP4800194B2 (ja) 乾癬の治療薬を製造するためのカハラリド化合物の使用
Parr et al. Allogeneic bone marrow transplantation: procedures and complications
JP5523707B2 (ja) 虚血性再灌流傷害または多臓器不全の治療または予防方法
BR0114642A (pt) Prevenção de doenças através da reativação do timo
ES2356371T3 (es) Medicamentos terapéuticos para inducir tolerancia.
Brenner et al. A novel antigen-toxin chimeric protein: myelin basic protein-pseudomonas exotoxin (MBP-PE 40) for treatment of experimental autoimmune encephalomyelitis
AR022348A1 (es) Una composicion farmaceutica para el tratamiento de los sintomas del tracto urinario inferior
AR025549A1 (es) Mofetil micofelonato en asociacion con peg-ifn-alfa
US20170079950A1 (en) Methods of Managing Graft Versus Host Disease (GvHD) Using Indole Carboxyaldehydes or Derivatives Thereof
BR0113140A (pt) Antagonistas de receptor de ccr1 não peptìdico em combinação com ciclosporina a para o tratamento da rejeição de transplante de coração
CA2246744C (fr) Complexe immunomodulateur et son utilisation dans les affections par helicobacter

Legal Events

Date Code Title Description
FG Grant, registration